NovImmune, AveXis, bluebird bio,and Loxo Oncologyare all close to filing for potential approval in the EU investigational therapies that they hope will be fast-tracked through the system.
The products include two gene therapies: onasemnogeneabeparvovec (AveXis, recently acquired by Novartis) and LentiGlobin (bluebird bio). The other two...






